Kessler Foundation study compares neuropsychological tests for assessing deficits in MS
(Kessler Foundation) Kessler Foundation researchers compared two neuropsychological tests for assessing learning in individuals with multiple sclerosis. 'Comparing the Open Trial - Selective Reminding Test results with the California Learning Verbal Test II in Multiple Sclerosis' was published online on April 4, 2018, in Applied Neuropsychology: Adult. This is the first study to compare the two tests in the same individuals with MS. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 24, 2018 Category: International Medicine & Public Health Source Type: news

Leg exercise is critical to brain and nervous system health
(Frontiers) New research shows that using the legs, particularly in weight-bearing exercise, sends signals to the brain that are vital for the production of healthy neural cells. The groundbreaking study fundamentally alters brain and nervous system medicine -- giving doctors new clues as to why patients with motor neuron disease, multiple sclerosis, spinal muscular atrophy and other neurological diseases often rapidly decline when their movement becomes limited. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - May 23, 2018 Category: International Medicine & Public Health Source Type: news

Various Clinical Disturbances Precede MS Diagnosis
FRIDAY, May 18, 2018 -- Various clinical symptoms precede the diagnosis of multiple sclerosis (MS) by several years, according to a study published online May 8 in the Annals of Neurology. Giulio Disanto, M.D., Ph.D., from the Neurocentre of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 18, 2018 Category: Pharmaceuticals Source Type: news

The influence of THC:CBD oromucosal spray on driving ability in patients with multiple sclerosis-related spasticity - Celius EG, Vila C.
BACKGROUND: Driving ability is a key function for the majority of patients with multiple sclerosis (MS) to help maintain daily interactions. Both physical and cognitive disability, as well as treatments, may affect the ability to drive. Spasticity is a com... (Source: SafetyLit)
Source: SafetyLit - May 18, 2018 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news

Medical News Today: Gut bacteria offer clues to multiple sclerosis
Researchers examine connections between the brain, gut, and immune system. Their findings offer clues about how diet influences brain inflammation. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - May 18, 2018 Category: Consumer Health News Tags: GastroIntestinal / Gastroenterology Source Type: news

NICE approves multiple sclerosis drugs after prices are reduced
Reductions to the price of three multiple sclerosis (MS) drugs mean NICE is now able to recommend them for routine NHS funding. (Source: NHS Networks)
Source: NHS Networks - May 18, 2018 Category: UK Health Source Type: news

T Helper 17.1 Cells Associate With MS Disease Activity T Helper 17.1 Cells Associate With MS Disease Activity
The findings of this study suggest a strong rationale for more specific and earlier use of T cell-targeted therapy in multiple sclerosis.Brain (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 17, 2018 Category: Consumer Health News Tags: Neurology & Neurosurgery Journal Article Source Type: news

Researchers Uncover Gut Bacteria's Potential Role In Multiple Sclerosis
Molecules produced from the breakdown of food by gut bacteria have been shown for the first time to directly affect cells in the central nervous system. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - May 16, 2018 Category: Pharmaceuticals Authors: Victoria Forster, Contributor Source Type: news

Microbes Affect Brain Cells Activities in Mice with Multiple Sclerosis
Researchers find a link between molecules released by commensal bacteria and the degree of inflammation in a mouse model of MS. (Source: The Scientist)
Source: The Scientist - May 16, 2018 Category: Science Tags: Daily News Source Type: news

Medical News Today: What causes multiple sclerosis? Landmark study finds clue
Multiple sclerosis is an autoimmune disease, the causes of which remain mysterious. But a new study may now have uncovered a key factor in its development. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - May 16, 2018 Category: Consumer Health News Tags: Multiple Sclerosis Source Type: news

First clues to the causes of multiple sclerosis
Multiple sclerosis, which affects 1 in 1,000 people, is frequently characterised by relapses associated with variable functional impairments including among others vision problems, impairment of locomotor functions or difficulties with speech. There is still no cure for multiple sclerosis, with current treatments largely based on managing symptoms, especially accelerating recovery phases following a relapse and reducing the number and severity of relapses. (Source: World Pharma News)
Source: World Pharma News - May 15, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

FDA Expands Use of MS Drug to Include Children
MONDAY, May 14, 2018 -- The U.S. Food and Drug Administration has expanded its approval of the multiple sclerosis drug Gilenya (fingolimod) to include children aged 10 and older. It's the first multiple sclerosis drug approved for children, the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 14, 2018 Category: Pharmaceuticals Source Type: news

Gaze stability, dynamic balance and participation deficits in people with multiple sclerosis at fall-risk - Garg H, Dibble LE, Schubert MC, Sibthorp J, Foreman KB, Gappmaier E.
Despite the common complaints of dizziness and demyelination of afferent or efferent pathways to and from the vestibular nuclei which may adversely affect the angular Vestibulo-Ocular Reflex (aVOR) and vestibulo-spinal function in persons with Multiple Scl... (Source: SafetyLit)
Source: SafetyLit - May 14, 2018 Category: International Medicine & Public Health Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news

Use of MS Drug, Gilenya (Fingolimod), Expanded to Include Children
MONDAY, May 14, 2018 -- The U.S. Food and Drug Administration has expanded its approval of the multiple sclerosis drug Gilenya (fingolimod) to include children aged 10 and older. It's the first multiple sclerosis drug approved for children, the... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - May 14, 2018 Category: General Medicine Source Type: news

FDA Okays Fingolimod (Gilenya), First Treatment for Pediatric MS FDA Okays Fingolimod (Gilenya), First Treatment for Pediatric MS
The FDA has expanded approval of the oral agent fingolimod from treatment for adults to treatment for children and adolescents aged 10 and up with multiple sclerosis.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 11, 2018 Category: Consumer Health News Tags: Neurology & Neurosurgery News Alert Source Type: news

FDA Expands Approval of Gilenya (fingolimod) to Treat Multiple Sclerosis in Pediatric Patients
May 11, 2018 -- The U.S. Food and Drug Administration today approved Gilenya (fingolimod) to treat relapsing multiple sclerosis (MS) in children and adolescents age 10 years and older. This is the first FDA approval of a drug to treat MS in... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 11, 2018 Category: Drugs & Pharmacology Source Type: news

Fingolimod OK'd for Pediatric MS
(MedPage Today) -- First drug approved for multiple sclerosis in kids 10 and older (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - May 11, 2018 Category: American Health Source Type: news

FDA expands use of Novartis MS drug to pediatric patients
(Reuters) - The U.S. Food and Drug Administration (FDA) on Friday expanded the use of Novartis AG's relapsing multiple sclerosis (MS) drug Gilenya to treat children and adolescents. (Source: Reuters: Health)
Source: Reuters: Health - May 11, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

FDA expands approval of Gilenya to treat multiple sclerosis in pediatric patients
FDA approves Gilenya (fingolimod) to treat multiple sclerosis MS in children age 10 and older. This is the first FDA approval of a drug to treat MS in pediatric patients (Source: Food and Drug Administration)
Source: Food and Drug Administration - May 11, 2018 Category: American Health Source Type: news

FDA expands approval of Gilenya to treat multiple sclerosis in pediatric patients
The U.S. Food and Drug Administration today approved Gilenya (fingolimod) to treat relapsing multiple sclerosis (MS) in children and adolescents age 10 years and older. This is the first FDA approval of a drug to treat MS in pediatric patients. (Source: World Pharma News)
Source: World Pharma News - May 11, 2018 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

FDA Lays the Smackdown on Illegal Stem Cell Clinics
FDA is cracking down on stem cell clinics that market unapproved products and don't meet good manufacturing practice requirements. On behalf of the agency, the Department of Justice filed two complaints in federal court this week seeking permanent injunctions against a Florida-based clinic and a California-based clinic.  “Cell-based regenerative medicine holds significant medical opportunity, but we’ve also seen some bad actors leverage the scientific promise of this field to peddle unapproved treatments that put patients’ health at risk. In some instances, patients have suffered serious and per...
Source: MDDI - May 10, 2018 Category: Medical Devices Authors: Amanda Pedersen Tags: Regulatory and Compliance Source Type: news

Akili Interactive closes $55m Series C
Akili Interactive said today it closed a $55 million Series C round of financing to help support its novel digital treatments for cognitive dysfunction. The round was led by Temasek and joined by Baillie Gifford, Amgen Ventures, M Ventures, Jazz Venture Partners, Canepa Advanced Healthcare Fund and Brooklands Capital Strategies, the Boston-based company said. Akili said that the Series C round follows the release of top-line results from a study of the company’s AKL-T01 flagship investigational product designed to treat pediatric attention deficit/hyperactivity disorder, released last December. The company said it pl...
Source: Mass Device - May 9, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Neurological Software / IT Akili Interactive Labs Source Type: news

Duped Patients Crowdfund for Fraudulent Medical Care, Study Says
CHICAGO (AP) — They're the tech-age version of donor jars at the diner: crowdfunding websites that aim to link ailing people with strangers willing to help pay for medical treatment. But new research suggests duped patients sometimes crowdfund to pay for bogus stem cell treatments. A study published Tuesday in the Journal of the American Medical Association focused on for-profit clinics that use direct-to-consumer advertising for costly unproven stem-cell treatments for conditions including chronic lung disease, Parkinson's disease, multiple sclerosis and arthritis. Treatments are often marketed as cures or with a pr...
Source: JEMS Patient Care - May 8, 2018 Category: Emergency Medicine Authors: Lindsey Tanner, Associated Press Tags: Patient Care News Source Type: news

Duped Patients Crowdfund for Fraudulent Medical Care, Study Says
CHICAGO (AP) — They're the tech-age version of donor jars at the diner: crowdfunding websites that aim to link ailing people with strangers willing to help pay for medical treatment. But new research suggests duped patients sometimes crowdfund to pay for bogus stem cell treatments. A study published Tuesday in the Journal of the American Medical Association focused on for-profit clinics that use direct-to-consumer advertising for costly unproven stem-cell treatments for conditions including chronic lung disease, Parkinson's disease, multiple sclerosis and arthritis. Treatments are often marketed as cures or with a pr...
Source: JEMS: Journal of Emergency Medical Services News - May 8, 2018 Category: Emergency Medicine Authors: Lindsey Tanner, Associated Press Tags: Patient Care News Source Type: news

Our vulnerable nervous system: What affects its protective sheaths?
(University of Erlangen-Nuremberg) Multiple sclerosis is a serious neurological condition that has no known cure. Although the causes are far from being known, we do know that the immune system erroneously attacks the protective sheaths around nerve fibres. Scientists at Friedrich-Alexander-Universit ä t Erlangen-N ü rnberg have discovered how the formation of myelin sheaths is regulated by protein molecules. This knowledge could be used to help MS patients by stimulating the formation of new myelin sheaths after a relapse. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - May 8, 2018 Category: Biology Source Type: news

Binky Felstead ’s mother Jane reveals she plans to DIE at 85
Speaking on ITV's Good Morning Britain on Monday, the 66-year-old revealed that her battle with  Multiple Sclerosis has made her dread becoming infirm and reliant on her children in her old age. (Source: the Mail online | Health)
Source: the Mail online | Health - May 7, 2018 Category: Consumer Health News Source Type: news

UCalgary scientists discover a new way to battle multiple sclerosis
(University of Calgary) University of Calgary scientists Andrew Caprariello, Ph.D., and Dr. Peter Stys, professor at the Cumming School of Medicine, are challenging conventional thinking about the root cause of multiple sclerosis. Their findings show there may be something happening deeper and earlier that damages myelin and then later triggers immune attacks. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 7, 2018 Category: International Medicine & Public Health Source Type: news

WATCH: Meredith Vieira, Richard Cohen on battle with MS
Vieira and her husband discuss his inspiring book about living with multiple sclerosis for over 40 years. (Source: ABC News: Health)
Source: ABC News: Health - May 3, 2018 Category: Consumer Health News Tags: theview Source Type: news

Fracking the Immune System
Researchers at the University of Rochester Medical Center are the first to report links between early life exposure to chemicals in ground water near fracking sites and immune system imbalances in mice. Their findings suggest that exposure to these chemicals during development may adversely affect the immune system ’s ability to fight diseases like multiple sclerosis later in life. (Source: University of Rochester Medical Center Press Releases)
Source: University of Rochester Medical Center Press Releases - May 1, 2018 Category: Universities & Medical Training Authors: University of Rochester Medical Center Source Type: news

Three multiple sclerosis drugs recommended by NICE
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - May 1, 2018 Category: Drugs & Pharmacology Source Type: news

Roche reports a strong start in 2018
Roche (SIX: RO, ROG; OTCQX: RHHBY) has announced that in the first three months of 2018, Group sales rose 6% to CHF 13.6 billion. Sales in the Pharmaceuticals Division increased 7% to CHF 10.7 billion. A key growth driver was Ocrevus, used to treat two forms of multiple sclerosis. It continued its strong growth in the US and was launched in Europe and additional countries worldwide during the first quarter. (Source: World Pharma News)
Source: World Pharma News - April 30, 2018 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news

The relationship between physiological and perceived fall risk in people with multiple sclerosis: implications for assessment and management - Gunn H, Cameron M, Hoang P, Lord S, Shaw S, Freeman J.
This study evaluated the relationship between physiological and perceived fall risk in people with MS. DESIGN: Secondary analysis of data from prospective cohort studies undertaken in Australia, United Kingdom and the United States. SETT... (Source: SafetyLit)
Source: SafetyLit - April 30, 2018 Category: International Medicine & Public Health Tags: Falls Source Type: news

What Causes Flushing?
Discussion Flushing is usually thought of as a benign condition such as blushing, but can be quite irritating if it is frequent or persistent (i.e. menopausal hot flashes) or even pathologic (i.e. malignancy). “Flushing is a subjective and sensation of warmth that is accompanied by reddening of the skin anywhere on the body but favors the face, neck, and upper torso…. Flushing can be broadly divided into episodic or persistent. Episodic flashing is mediated by the release of endogenous vasoactive mediators or medications, while persistent flushing result in a fixed facial erythema with telangiectasias and cyan...
Source: PediatricEducation.org - April 30, 2018 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

Study: MS drug may diminish side effects in myeloma treatment
A drug commonly used to treat multiple sclerosis could reduce the effects of a chemotherapy of myeloma patients, according to a study of mice. (Source: Health News - UPI.com)
Source: Health News - UPI.com - April 27, 2018 Category: Consumer Health News Source Type: news

Multiple sclerosis drug could reduce painful side effects of common cancer treatment
(Rockefeller University Press) Researchers from the Saint Louis University School of Medicine have discovered why many multiple myeloma patients experience severe pain when treated with the anticancer drug bortezomib. The study, which will be published April 27 in the Journal of Experimental Medicine, suggests that a drug already approved to treat multiple sclerosis could mitigate this effect, allowing myeloma patients to successfully complete their treatment and relieving the pain of myeloma survivors. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 27, 2018 Category: Cancer & Oncology Source Type: news

MRI Illuminates Novel Drug's Potential for Relapsing-Remitting MS MRI Illuminates Novel Drug's Potential for Relapsing-Remitting MS
MRI findings midway through a 2-year phase 3 trial reveal the promise of ALKS 8700 for reducing gadolinium-enhancing lesions among people with multiple sclerosis.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 26, 2018 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

Dimethyl fumarate targets GAPDH and aerobic glycolysis to modulate immunity
Activated immune cells undergo a metabolic switch to aerobic glycolysis akin to the Warburg effect, thereby presenting a potential therapeutic target in autoimmune disease. Dimethyl fumarate (DMF), a derivative of the Krebs cycle intermediate fumarate, is an immunomodulatory drug used to treat multiple sclerosis and psoriasis. Although its therapeutic mechanism remains uncertain, DMF covalently modifies cysteine residues in a process termed succination. We found that DMF succinates and inactivates the catalytic cysteine of the glycolytic enzyme glyceraldehyde 3-phosphate dehydrogenase (GAPDH) in mice and humans, both in vi...
Source: ScienceNOW - April 26, 2018 Category: Science Authors: Kornberg, M. D., Bhargava, P., Kim, P. M., Putluri, V., Snowman, A. M., Putluri, N., Calabresi, P. A., Snyder, S. H. Tags: Immunology, Medicine, Diseases reports Source Type: news

Medical News Today: Sheep disease toxin shines a light on multiple sclerosis
A sheep disease has parallels with multiple sclerosis. A study identifies antibodies to the toxin in humans, providing clues as to the condition's origin. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - April 25, 2018 Category: Consumer Health News Tags: Multiple Sclerosis Source Type: news

Mother Forms Company to Tackle Brain-Based Disorders
What do you do when you have a child that’s suffering from a neurological disorder and nothing seems to work? What do you do when each visit to the doctor leads to more questions and more confusions. It’s a scenario that no mother wants to go through, yet Malekeh Amini found herself in with her son. “He was diagnosed with one neurological disorder at the age of 5, then another when he was six and another,” Amini told MD+DI. “It just continued to become more and more complex. After running around from one clinic to another and not knowing how to manage his symptoms and not knowing really how to...
Source: MDDI - April 24, 2018 Category: Medical Devices Authors: Omar Ford Tags: Digital Health Business Source Type: news

HBS Mom Forms Company to Tackle Brain-Based Disorders Through Data Analytics
What do you do when you have a child that’s suffering from a neurological disorder and nothing seems to work? What do you do when each visit to the doctor leads to more questions and more confusions. It’s a scenario that no mother wants to go through, yet Malekeh Amini found herself in with her son. “He was diagnosed with one neurological disorder at the age of 5, then another when he was six and another,” Amini told MD+DI. “It just continued to become more and more complex. After running around from one clinic to another and not knowing how to manage his symptoms and not knowing really how to...
Source: MDDI - April 24, 2018 Category: Medical Devices Authors: Omar Ford Tags: Digital Health Business Source Type: news

Guidelines Developed for Use of Drugs in Multiple Sclerosis
TUESDAY, April 24, 2018 -- Guidelines have been developed for use of disease-modifying therapies (DMTs) in multiple sclerosis (MS), integrating findings from a systematic review. The review and guidelines were published online April 23 in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 24, 2018 Category: Pharmaceuticals Source Type: news

New OCREVUS (ocrelizumab) data at AAN demonstrate significant reductions in disease activity and disability progression in relapsing multiple sclerosis
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that new OCREVUS (ocrelizumab) data were presented at the 70th American Academy of Neurology (AAN) Annual Meeting from 21-27 April in Los Angeles, California. The data showcase the efficacy of OCREVUS in relapsing multiple sclerosis (RMS) through several measures of underlying disease activity and disability progression, including magnetic resonance imaging (MRI), cognitive function, and spinal fluid biomarkers of inflammation and neurodegeneration. (Source: World Pharma News)
Source: World Pharma News - April 24, 2018 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news

New AAN Guidelines Advocate Early MS Treatment New AAN Guidelines Advocate Early MS Treatment
New guidelines update guidance on starting, switching, and stopping disease-modifying therapies in multiple sclerosis and recommend an earlier, rather than later, start to treatment.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 23, 2018 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

Start MS Drugs Early, New Guideline Says
(MedPage Today) -- AAN updates multiple sclerosis treatment recommendations (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - April 23, 2018 Category: Neurology Source Type: news

The Dyad-Adaptive Paced Auditory Serial Addition Test (DA-PASAT): normative data and the effects of repeated testing, simulated malingering, and traumatic brain injury - Woods DL, Wyma JM, Herron TJ, Yund EW, Reed B.
The Paced Auditory Serial Addition Test (PASAT) is widely used to evaluate processing speed and executive function in patients with multiple sclerosis, traumatic brain injury, and other neurological disorders. In the PASAT, subjects listen to sequences of ... (Source: SafetyLit)
Source: SafetyLit - April 23, 2018 Category: International Medicine & Public Health Tags: Research Methods, Surveillance and Codes, Models Source Type: news

Don't Wait to Take MS Drugs
MONDAY, April 23, 2018 -- Most multiple sclerosis patients shouldn't wait to start taking medication in the early stages of the disease, new guidelines say. " The treatment landscape for people with MS has changed dramatically over the last decade, " ... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 23, 2018 Category: General Medicine Source Type: news

New OCREVUS (ocrelizumab) data at AAN demonstrate significant reductions in disease activity and disability progression in relapsing multiple sclerosis
Roche announced today that new OCREVUS (ocrelizumab) data were presented at the 70th American Academy of Neurology (AAN) Annual Meeting from 21-27 April in Los Angeles, California. (Source: Roche Media News)
Source: Roche Media News - April 23, 2018 Category: Pharmaceuticals Source Type: news

New OCREVUS (ocrelizumab) data at AAN demonstrate significant reductions in disease activity and disability progression in relapsing multiple sclerosis
Roche announced today that new OCREVUS (ocrelizumab) data were presented at the 70th American Academy of Neurology (AAN) Annual Meeting from 21-27 April in Los Angeles, California. (Source: Roche Investor Update)
Source: Roche Investor Update - April 23, 2018 Category: Pharmaceuticals Source Type: news

New OCREVUS (ocrelizumab) data at AAN demonstrate significant reductions in disease activity and disability progression in relapsing multiple sclerosis
Roche announced today that new OCREVUS (ocrelizumab) data were presented at the 70th American Academy of Neurology (AAN) Annual Meeting from 21-27 April in Los Angeles, California. (Source: Roche Media News)
Source: Roche Media News - April 23, 2018 Category: Pharmaceuticals Source Type: news

Multiple sclerosis may be linked to sheep disease toxin
(University of Exeter) Exposure to a toxin primarily found in sheep could be linked to the development of multiple sclerosis (MS) in humans, new research suggests. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - April 22, 2018 Category: Infectious Diseases Source Type: news